SIRPA and neoplasm: The SIRPα expression of tumor-infiltrating myeloid cells exhibited a large decline in NAC-treated partial response (PR) groups and an increase in groups of NAC-treated patients with progressive disease (PD) or stable disease (SD) (Figure 10E).